Skip to content

Orion Group Financial Statement documents 2021, Corporate Governance Statement and Remuneration Report published

ORION CORPORATION STOCK EXCHANGE RELEASE / ANNUAL FINANCIAL REPORT 1 MARCH 2022 at 9.30 EET

Orion Group's Financial Statement documents for 2021 have been published. The documents are available in Finnish and English on the Company's website at http://www.orion.fi/en and are attached to this release. The Financial Statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements as xHTML file. The primary statements of the Consolidated financial statements have been labelled with XBRL tags. Authorised Public Accountants KPMG Oy Ab has provided an independent auditor’s reasonable assurance report on Orion’s ESEF Financial Statements in accordance with ISAE 3000.

The official Financial Statement documents in accordance with the requirements of the Finnish Accounting Act and the Companies Act, which include the Financial Statements, the Report by the Board of Directors and the Auditor's Report are available in Finnish at http://www.orion.fi/yhtiokokous2022.

Orion's Corporate Governance Statement 2021 and Remuneration Report 2021, both adopted by the Board of Directors, have also been published as separate reports in Finnish and English on the Company's website at http://www.orion.fi/en and are attached to this release.

Orion Corporation

Olli Huotari
SVP, Corporate Functions 		  Terhi Ormio
VP, Communications 		 

                                                
Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Attachments